Darshan Godkar, MD
Interventional Cardiology · Cedar Knolls, NJNPI 1952515264
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $166,659 of the $194,043 with a category attached, or 85.9%. 54 manufacturers reported payments, led by Amgen at 35.6% of the total. Among interventional cardiology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 856 payments — averaging $226.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$69K
- Boehringer Ingelheim$60K
- Johnson & Johnson$19K
- Boston Scientific$18K
- Lilly USA, LLC$10K
- Medtronic$7K
- plus $11K from 48 others
Across 38 payments — averaging $1748.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$37K
- Boehringer Ingelheim Pharma GmbH & Co.kg$21K
- Cvrx, Inc.$4K
- Boehringer Ingelheim International GmbH$4K
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$166,65986%
- Travel & lodging$4,3132%
- Food & beverage$22,73812%
- Education$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$68,408
- Repatha$67,779
- XARELTO$17,970
- Watchman$10,598
- WATCHMAN Access System$4,260
- COREVALVE EVOLUT R$3,083
- CoreValve Evolut$2,181
- EVOQUE$1,023
- WATCHMAN FLX$951
- Indigo System$794
- MitraClip$652
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$534
- Confirm Rx$314
- MitraClip System$271
- ACCENT$146
- SYNERGY$144
- Barostim Neo System$134
- GENERAL - THERAPIES$114
- JOT DX$114
- Wegovy$112
How this compares
$194,043 in reported general payments places this provider in the 95th percentile of 166 interventional cardiology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 265 | $325,895 |
| EliquisApixaban | 245 | $276,732 |
| EntrestoSacubitril/Valsartan | 175 | $209,040 |
| XareltoRivaroxaban | 150 | $184,140 |
| JardianceEmpagliflozin | 135 | $175,549 |
| OzempicSemaglutide | 45 | $65,824 |
| BrilintaTicagrelor | 50 | $46,111 |
| Praluent PenAlirocumab | 32 | $32,938 |
| MultaqDronedarone Hcl | 12 | $28,012 |
| Metoprolol Succinate | 1,096 | $19,638 |
| MounjaroTirzepatide | 16 | $18,498 |
| Droxidopa | 13 | $18,076 |
| FarxigaDapagliflozin Propanediol | 14 | $14,975 |
| Rosuvastatin Calcium | 1,047 | $14,547 |
| Repatha PushtronexEvolocumab | 22 | $13,863 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $106 | $276,732245 claims |
| NovartisEntresto | $863 | $209,040175 claims |
| Johnson & JohnsonXarelto | $18,874 | $184,140150 claims |
| Boehringer IngelheimJardiance | $59,838 | $175,549135 claims |
| AstraZenecaBrilinta, Farxiga, Crestor | $441 | $73,27194 claims |
| Novo NordiskOzempic | $433 | $65,82445 claims |
| Sanofi-aventis U.S. LLCMultaq | $264 | $28,01212 claims |
| Lilly USA, LLCMounjaro | $9,976 | $18,49816 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $245 | $9,68120 claims |
| AmgenCorlanor | $69,083 | $9,65612 claims |
| MerckJanuvia | $582 | $8,47911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 166 interventional cardiology providers in New Jersey.
Other interventional cardiology in Cedar Knolls
- Sumit SomCedar Knolls$36K
- Jason KaplanCedar Knolls$15K
- Ankitkumar PatelGlen Ridge$408K
- Ziad AbbudOcean$360K
- Ramin HastingsHasbrouck Heights$295K
- Michael LimHackensack$215K
- Ryan KapleHackensack$178K
- Matthew SayboltEatontown$175K
- Daniel KissEatontown$172K
- Kintur SanghviBordentown$139K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.